Unicycive Therapeutics, Inc. UNCY
4.70
(0.11)
(2.29%)
as of 25 Sep
- Market cap
- $134.0M
- P/E
- 0.0×
Follow UNCY
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (101.07%) | (163.14%) | (141.14%) | (84.15%) |
+8 more TTM periods Free account |
|
| (69.05%) | (86.51%) | (65.73%) | (61.64%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(66.89%) | (107.65%) | (88.25%) | (73.83%) | |
Free Cash Flow per Share |
(1.03) | (1.20) | (1.97) | (1.65) | |
Free Cash Flow |
(27.85) | (28.67) | (31.34) | (29.88) | |
Capital Expenditures |
(0.01) | (0.02) | (0.02) | (0.05) | |
| Other line items | |||||
Cash ROIC |
(24.27%) | (31.05%) | (43.82%) | (37.21%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.79 | 0.72 | 1.18 | 1.09 | |
Depreciation/Fixed assets |
15.61 | 13.75 | 8.67 | 7.40 | |
Capex/Depreciation |
(0.01) | (0.02) | (0.04) | (0.08) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.03) | (1.20) | (1.97) | (1.65) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates